JBT Marel Corp

JBTM remains in a healthy Stage 2 uptrend with medium- and long-term bullish structure intact, but recent price pullback into the flat-to-declining EMA band and sideways short-term trend suggest timing is unfavorable. We will defer entry and await clear acceptance off the 9/21/50 EMA zone before initiating new exposure.

• ↑Poultry segment orders rose 12% YoY, pushing intake above $1 billion
• ↑Merger synergies of $150 million targeted, boosting adjusted EBITDA margin to 17–17.5% by 2026
• ↓Negative profitability factors raise cost management concerns amid tariff pressures